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Introduction: The Global Organization of Lung Disease (GOLD) classifies patients with 
chronic obstructive pulmonary disease (COPD) taking into account the symptoms. The 
modified Medical Research Council’s dyspnea scale (mMRC) and the COPD assessment 
test (CAT) are used to assess these symptoms. In this study, we analyze the concordance of 
GOLD classification using mMRC and CAT.
Patients and Methods: This is an observational study of a cohort of 169 patients with 
COPD, who were classified following the GOLD 2017 recommendations, using both mMRC 
and CAT. A concordance analysis was applied, and a ROC curve was generated to identify 
the CAT score that best concorded with the mMRC scale.
Results: The concordance for the GOLD groups classified by CAT and mMRC was 
moderate (kappa 0.492). For mMRC score of 1 and 2, a CAT score of ≥9 and ≥16 showed 
the maximum value of the Youden index, respectively. By reclassifying the patients with the 
new cut-off points obtained, the best concordance was obtained between the cut-off point for 
CAT of 16 and for mMRC of 2, followed by CAT of 9 and mMRC of 1.
Conclusion: Because of the deficient concordance between CAT and mMRC, we propose 
the use of new cut-off points in future updates of the GOLD strategy.
Keywords: chronic obstructive pulmonary disease, COPD, Global Organization of Lung 
Disease, GOLD, dyspnea, modified Medical Research Council, mMRC, COPD assessment 
test, CAT
Introduction
The World Health Organization (WHO) describes chronic obstructive pulmonary 
disease (COPD) as a progressive lung disease that can cause life-threatening dyspnea 
and predisposes to suffer exacerbations and serious illnesses. It is estimated that about 
3 million people worldwide died of this cause in 2015, representing 5% of all deaths 
recorded that year. The main cause of COPD is exposure to tobacco smoke.1
The GOLD strategy (Global initiative for the Diagnosis, Management, and 
Prevention of Chronic Obstructive Lung Disease) is an international reference docu-
ment for the management of COPD.2 In recent years it has undergone significant 
changes in light of new scientific evidence, especially on issues related to the diagnosis 
and classification of disease. All of this has contributed to improving the global 
approach to COPD.
The first GOLD report was published in 2001 and proposed a classification of 
severity of COPD based on spirometry and arterial blood gas abnormalities.3 
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Spirometry remained the gold standard for diagnosis, clas-
sification and follow-up of the COPD patient until the 
document was updated in 2011.4 In this edition, spirometry 
was maintained as a method for diagnosing subjects with 
suspected COPD and a new classification system was 
proposed that combined symptoms, comorbidities, risk of 
exacerbations and lung function (ABCD). Despite the 
ABCD proposal was relatively well received, it was criti-
cized for some aspects that were controversial. Thus, this 
classification was more complex and did not offer any 
advances in determining the prognosis of patients com-
pared to the previous version.5 In this sense, some studies 
suggested that there would probably be an improvement in 
the prediction of exacerbations, but these results were not 
reproduced in predicting mortality or decreased lung 
function.6
Based on the above, one of the main changes introduced 
in the 2017 update was the introduction of a new diagnostic 
algorithm in which lung function was removed from all four 
quadrants of the ABCD classification. According to this 
classification, patients were stratified with either mMRC 
score (0–1 vs ≥2) or CAT score (<10 or ≥10) resulting in 
two low-symptom categories (A and C) and two high- 
symptom categories (B and D). The patient’s risk was then 
established based on the exacerbations and hospital admis-
sions suffered by the patient in the previous year. Patients 
who had suffered 0–1 exacerbation or no hospital admission 
in the previous year were stratified into groups A or B (low 
risk) and patients with ≥2 exacerbations or income prior year 
were stratified to groups C or D (high risk). Despite these 
changes, criticism of this model has also emerged. One is 
based on the choice of the tool used to measure the symp-
toms, either the Medical Research Council’s modified dys-
pnea scale (mMRC) or the COPD Assessment Test 
questionnaire (CAT). The GOLD strategy recommends 
using either mMRC or CAT, choosing one but not indicating 
the performance of both. In this regard, the assignment of 
a patient to a group may change depending on the symptom 
scale used.7
The COPD assessment test (CAT) is a short questionnaire 
developed to help patients and clinicians to assess the impact 
of symptoms in routine clinical practice. It consists of eight 
items and each item has a score from 0 to 5. An overall score 
is calculated by adding the score from each item; a total score 
ranging from 0 to 40. The higher the score, the worse the 
subject’s health status.8 The CAT questionnaire presents 
excellent internal consistency and a very good correlation 
with the Saint George Respiratory Questionnaire (SGRQ) 
specific for COPD.9 The correlation of the CAT with the 
SGRQ has made it possible to establish that a value of 10 
points (equivalent to 25 points on the SGRQ questionnaire) 
should be used as a cut-off point below which the disease has 
a low impact on the subject’s health.10
The mMRC dyspnoea scale is an assessment tool that 
establishes the severity of this symptom in relation to 
various physical tasks. This scale was developed by the 
American Thoracic Society as a modification of the ori-
ginally proposed British Medical Research Council dys-
pnea index (scale 1–5). It consists of five items and its 
value is set in a range from 0 (No dyspnea or dyspnea only 
with strenuous exercise) to 4 (dyspnea at rest).11,12 As the 
scale is one-dimensional and focuses only on respiratory 
distress, it may lose accuracy in older patients or major co- 
morbidities such as obesity, osteoarticular disease, or anxi-
ety and depression disorders.13
The GOLD strategy considered an mMRC dyspnea scale 
score of 2 and a CAT score of 10 to be equivalent, despite the 
fact that there were no studies to support these data.
The purpose of our study is to find out if the classifica-
tion of COPD patients into a group (ABCD) could change 
depending on the symptom scale used. Another objective 
is to determine whether the cut-off points set at 10 for the 
CAT questionnaire and 2 for the mMRC dyspnea scale, 
which separate mildly symptomatic and highly sympto-
matic patients, are the ideal cut-off points where there is 
the least degree of discrepancy between the two assess-
ment tools.
Patients and Methods
The observational study included COPD patients followed- 
up in pneumology outpatient department. Demographic, clin-
ical and functional variables were analyzed in patients with 
stable COPD. Sequential sampling and inclusion of all sub-
jects presenting with a diagnosis of COPD (newly diagnosed 
patients and follow-up patients) were performed.
Diagnosis of COPD was established by spirometry 
according to the GOLD criteria: post-bronchodilator FEV1/ 
FVC<0.7, history of smoking more than 10 pack-year and 
presence of respiratory symptoms. We did not consider 
COPD patients due to exposures other than tobacco because 
this is the main cause at present and the difficulty of doc-
umenting the wide range of exposures to other substances. 
Patients who had suffered an exacerbation of COPD in the 
last month were excluded to avoid the score on the CAT and 
mMRC dyspnea scale being influenced by the exacerbation.
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Those with active respiratory disorders such as pneu-
monia, diffuse bronchiectasis and interstitial lung disease 
seen on chest radiograph or chest computed tomography 
were also excluded, so that the respiratory symptoms 
produced by these diseases do not interfere with the scores 
of the CAT and mMRC scales related to COPD. Patients 
must have had the ability to undertake spirometry and 
answer the CAT questionnaire and the mMRC dyspnea 
scale. The period of inclusion of patients was from 
September 2017 to December 2018.
Subjects were classified according to GOLD 2017 
recommendations in ABCD. This classification was per-
formed on two occasions using the two recommended 
tools for measuring symptoms, the CAT questionnaire 
and the mMRC dyspnea scale. Both were applied on the 
same day and by the same interviewer.
Statistic Analysis
A descriptive analysis of the characteristics of the patients 
included was carried out. Quantitative variables are pre-
sented as mean and standard deviation (SD). The ANOVA 
test was used to compare the means of clinical and func-
tional variables of the four GOLD categories.
The degree of agreement when applying both evalua-
tion instruments to our cohort was calculated with the 
Kappa coefficient (k).The interpretation of agreement in 
this study is based on kappa value as described previously 
in the literature in which k=0 is “poor”, 0.01<k< 0.20 is 
“slight”, 0.21<k<0.40 is “fair”, 0.41<k< 0.60 is “moder-
ate”, 0.61<k< 0.80 is “substantial”, 0.81<k< 1.00 is 
“almost perfect”, and k=1 is “perfect” agreement.14
In addition, the Spearman correlation (non-parametric 
rho estimator) was used to assess the consistency between 
the two evaluation methods collected in the qualitative 
ordinal scale.
A receiver operating characteristics (ROC) curve was 
generated to identify the CAT questionnaire score that best 
correlated with the mMRC scale. The Youden index was 
used to find the cut-off point for the best combination of 
sensitivity and specificity. The analyses were performed 
with the SPSS statistical program. Values of p<0.05 
(2-tailed) were taken as significant in all comparisons.
Ethics Committee and Informed Consent
The study was approved by the Ethics Committee of the 
Hospital Universitario Puerta de Hierro Majadahonda de 
Madrid (Acta nº 02.18). Patients gave their signed 
informed consent before participating in the study.
This study was conducted in accordance with the 
Declaration of Helsinki.
Results
A total of 169 patients with COPD completed the ques-
tionnaire: CAT and mMRC dyspnea scale. The data on 
anthropomorphic, clinical and functional characteristics 
are shown in Table 1.
The cohort was classified according to the symptoms. 
The78.7% of patients were considered to be slightly sympto-
matic and 21.3% were considered to be very symptomatic 
when using the mMRC dyspnea scale. Patients were also 
classified using the CAT questionnaire and 43.2% were not 
Table 1 Baseline Patient Characteristics
Characteristics Value
Total 169
Age(years) 67.64 ± 9.77
Sex 116 males (68.6%) 
53 women (31.4%)
Active smoking 68 (40.2%)
Pack-years index 50 ± 24.58





Cardiovascular events 37 (22%)
Charlson Index 4 ± 1.5
CAT questionnaire 15.7 ± 7.32







FEV1 (%) 68.34 ± 20.96
FEV1(l) 1.76 ± 0.677
Bronchodilator test positive 30 (17.75%)
GOLD
Stage I 55 (32.5%)
Stage II 79 (46.9%)
Stage III 25 (14.8%)
Stage IV 10 (5.9%)
Abbreviations: BMI, body mass index; CAT, COPD assessment test; mMRC, 
modified Medical Research Council; FEV1, forced expiratory volume in 
one second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic 
Obstructive Lung Disease.
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highly symptomatic and 56.8% were highly symptomatic 
(Figure 1).
Using the mMRC dyspnea scale to classify patients into 
ABCD groups, 108 (63.9%) patients were assigned to group 
A, 18 (10.7%) to group B, 25 (14.8%) to group C and 18 
(10.7%) to group D. When the patients were classified 
according to the CAT questionnaire, 61 (36.1%) were 
assigned to group A, 65 (38.5%) to group B, 12 (7.1%) to 
group C and 31 (18.3%) to group D (Table 2).
The degree of agreement between the two GOLD 
groups was obtained with a kappa value of 0.492, which 
corresponds to a moderate agreement. The degree of con-
cordance between low-risk (A-B) and high-risk (C-D) 
patients was evaluated, obtaining a kappa value of 0.271 
and 0.436, respectively, showing that in low-risk patients 
the concordance is weaker than in high-risk patients.
The correlation between the mMRC dyspnea scale and 
the CAT questionnaire score was statistically significant 
(p<0.001), with a value of the Spearman correlation coef-
ficient of 0.661 (moderate-high correlation) (Figure 2). 
Despite this, we observed that there was a wide variation 
in the CAT score among patients with the same mMRC 
scale score (Figure 3).
In Table 3, taking as reference a score ≥10 in the CAT 
questionnaire, the variation of the degree of concordance was 
analyzed when modifying the cut-off point of dyspnea accord-
ing to the mMRC scale. By varying the cut-off point of the 
mMRC scale (≥1, ≥2, ≥3, ≥4) new groups (A, B, C and D) and 
new degrees of agreement were obtained. By analyzing the 
cut-off point of 2 in dyspnea according to the mMRC scale 
proposed by the guidelines, a group distribution of ABCD of 
108, 18, 25 and 18, respectively, was obtained, with a kappa 
value of 0.492. There was substantial agreement between the 
MRC dyspnea scale ≥1 with a CAT score ≥10 (kappa=0.623). 
The mMRC ≥1 value was the group with the highest degree of 
agreement. On the other hand, the mMRC value ≥4 was the 
group with the lowest degree of agreement, with a kappa 
value of 0.242.
A ROC curve was used to identify the CAT score that 
was best correlated with the mMRC scale. For an mMRC 
scale of 1, the best value was CAT ≥9, with a sensitivity 
and a specificity of 0.78 and 0.80, respectively (Figure 4). 
Figure 1 Classification of subjects according to symptoms.
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For an mMRC score of 2, a CAT score of 16 showed the 
maximum value of Youden’s index with a sensitivity and 
specificity of 0.80 and 0.85, respectively. (Area under 
curve -AUC- =0.878; 95% Confidence Interval -CI-: 
0.820 to 0.924).
By reclassifying the patients with the new cut-off 
points obtained, the highest value of the kappa was 
obtained between the cut-off point for CAT of 16 and for 
mMRC of 2 (kappa=0.71), followed by a kappa of 0.676 
for the cut-off point of the CAT questionnaire of 9 and of 
mMRC of 1 (Figure 5).
Discussion
The GOLD strategy recommends measuring the presence 
and intensity of symptoms by the CAT questionnaire or the 
mMRC dyspnea scale, choosing one of them but not 
indicating the performance of both. The cut-off points of 
mMRC ≥2 and CAT≥10 are considered the recommended 
cut-off points that separate symptomatic and slightly 
symptomatic patients, despite the fact that there is no 
scientific evidence that these cut-off points are similar.
The main conclusion of our study is that a cut-off point 
of 10 on the CAT questionnaire is not equivalent to a score 
on the mMRC dyspnea scale of 2, so the classification of 
COPD patients according to the GOLD recommendations 
is modified depending on the symptom scale used. This 
phenomenon of change or migration of patients from one 
group to another according to the symptom scale used was 
already described by Rieger-Reyes et al15, who identified 
that the use of one or another assessment method led to the 
reclassification of more than 25% of patients.
Discrepancy between the mMRC and CAT score is well 
described in previous studies. In our study, 35.51% of the 
patients were discordant, in other words, 35.51% of the 
subjects when classified by CAT and mMRC did not agree 
on their assignment within the groups A, B, C and D of the 
GOLD recommendations. This difference is important, since 
the recommended initial treatment depends on it. No differ-
ences were observed between these discordant and concor-
dant patients when analyzing their age, BMI, FEV1, year 
package index and Charlson’s index.
In our cohort, the agreement obtained between the CAT 
questionnaire and the mMRC dyspnea scale was moderate 
(κ = 0.492) and similar to that described in other studies.16 
In the subgroup analysis, concordance in the low-risk 
categories (A-B) was weak and increased to moderate in 
the high-risk categories (C-D). Furthermore, for each of 
the dyspnea scores, the CAT score presented a wide range 
of values. The degree of dispersion of the CAT score was 
greater in patients with dyspnea 0 and 1.
The highest concordance of the CAT questionnaire and 
the mMRC dyspnea scale in the high-risk groups has 
already been recorded in other studies, in which the 
group with more symptoms and high risk achieved better 
correlations than the group that combined fewer symptoms 
and low risk.17 In addition, a score on the questionnaire 
CAT≥10 occurs in up to 50% of individuals who smoke 
and ex-smoke without lower airway obstruction has been 
described.18
The mMRC breathlessness scale is a simple and easy 
scale. It correlates better with the quality of life of COPD 
patients than functional parameters.19 It also evaluates the 
efficacy of treatment and correlates closely with the 6-minute 
walk test and with 5-year survival in COPD patients.20,21
However, in its simplicity, there is its greatest limitation. 
The mMRC scale is one-dimensional and only focuses on 
breathing difficulty when measuring the magnitude of 
Table 2 Cohort Classification According to the 2017 GOLD 
Update for the mMRC Dyspnea Scale and the CAT 
Questionnaire
GOLD mMRC
GOLD CAT A B C D Total
A 61 0 0 0 61
B 47 18 0 0 65
C 0 0 12 0 12
D 0 0 13 18 31
Total 108 18 25 18 169
Abbreviations: GOLD, Global Initiative for Chronic Obstructive Lung Disease; 
CAT, COPD assessment test; mMRC, modified Medical Research Council.
Figure 2 Correlation between the CAT questionnaire and the mMRC dyspnea 
scale.
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symptoms. COPD affects patients beyond dyspnea; it is 
a complex and heterogeneous syndrome with pulmonary 
and extrapulmonary characteristics.
In this sense, the CAT questionnaire has the advantage 
of providing a multidimensional assessment of the impact 
of COPD on the patient.8 It is probably this dimensionality 
that explains the discrepancy between the two methods. 
Furthermore, the CAT cut-off points and their impact on 
health are well validated. Thus, scores in the questionnaire 
CAT<10 reflect a low impact in terms of the effect of the 
disease on the health of the patient; CAT values of ≥10 and 
<20 reflect a moderate impact; scores of CAT≥20 and <30 
indicate a high impact; and a value of CAT≥30 suggests 
a very high impact of COPD on the health of the patient.9
By taking a score on the CAT questionnaire ≥10 (recom-
mended) and varying the cut-off point of the mMRC scale, the 
degree of agreement (kappa) is modified according to the cut- 
off point of the mMRC dyspnea. If we compare the ≥2 score 
on the dyspnea scale, which is the recommended cut-off point 
according to the latest GOLD recommendations, and the 
mMRC score ≥1, we see how the concordance increases 
from moderate to substantial in relation to the recommended 
cut-off point. Other authors support these results, suggesting 
that an mMRC dyspnea scale of 1 would be more consistent 
with a value of CAT 10 than a score of 2.7,22
Figure 3 Histogram of CAT scores according to mMRC score.
Table 3 Distribution of Subjects Classified in Groups a, B, C and 
D According to the Cut-off Point Used for the mMRC Dyspnea 
Scale and Variation in Agreement (Kappa) with CAT 10 
(Reference)
A B C D Kappa
CAT ≥10 61 65 12 31 Reference
mMRC ≥ 1 34 92 6 37 0.623
mMRC ≥2 108 18 25 18 0.492
mMRC≥ 3 120 6 34 9 0.321
mMRC ≥ 4 124 2 40 3 0.242
Abbreviations: CAT, COPD assessment test; mMRC, modified Medical Research 
Council.
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Figure 4 ROC curves for dyspnea mMRC 1 and 2.
Figure 5 Classification of COPD patients according to the new cut-off points. *p <0.001.
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The new CAT cut-off points proposed in our study for 
the mMRC scores of ≥1 and ≥2 are ≥9 and ≥16, respec-
tively. By performing a new reclassification with the new 
cut-off points and applying a concordance analysis, better 
degrees of agreement were obtained between the CAT cut- 
off point and the mMRC dyspnea scale with respect to the 
reference ones. The highest kappa coefficient value is 
between the cut-off point of CAT≥16 and dyspnea 
mMRC≥2 (kappa=0.71), followed by a kappa coefficient 
of 0.676 for the cut-off point ≥9 and dyspnea mMRC≥1. 
These data would support the idea of redefining new cut 
points and making the appropriate modifications in the 
next GOLD review. By increasing the CAT score for 
dyspnea 1 and 2, the concordance increases, so the choice 
of the new cut-off point for CAT should be increased with 
respect to the mMRC dyspnea scale scores. By increasing 
the CAT score for dyspnea 1 and 2, the concordance 
increases, so the choice of the new cut-off point for CAT 
should be increased from the mMRC dyspnea scale scores.
Rhee et al16 described a new CAT cut-off point for an 
mMRC of 2. They showed that a CAT cut-off point of 15 
had a higher concordance for mMRC of 2, increasing from 
a CAT score of 10. These authors also noted that the 
concordance between an mMRC cut-off point of 1 and 
a CAT cut-off point of 10 was higher than for any of the 
other combinations and indicated that an mMRC cut-off 
point of 1 was more appropriate than a cut-off point of 2 
for defining the highly symptomatic patients. Other studies 
have established other cut-off points, proposing that an 
mMRC dyspnea of 2 would correspond with a CAT 
value ≥18, concluding that these changes would reclassify 
up to a third of patients.23
Our study has limitations. First, the sample size is 
relatively small due to the capacity of the center where 
the patients came from and the data have been collected in 
a single center; therefore, the results should be interpreted 
with caution. Another limitation is determined by the 
collection of patients. Subjects were referred from an out-
patient pneumology service, excluding patients who 
recently had an exacerbation (avoiding that the score on 
the CAT and mMRC dyspnea scale was influenced by the 
exacerbation). In this way, exacerbation patients or those 
who had recently been admitted and who attended our 
consultations were excluded. Despite this, this is 
a descriptive observational study in which the number of 
exacerbations and hospital admissions in the previous 
months has been recorded. Furthermore, it is based on 
actual data from daily clinical practice, representing the 
actual distribution of COPD groups. On the other hand, the 
study was conducted by respiratory specialists, with 
a rigorous design and with spirometry performed in 
a respiratory function laboratory, following the criteria of 
the American Thoracic Society (ATS).
In conclusion, the classification of COPD patients into 
GOLD revision varies according to the assessment method 
(CAT or mMRC) used to measure the intensity and pre-
sence of symptoms. A CAT score of 10 and the mMRC 
dyspnea scale of 2 are not equivalent cut-off points. In this 
sense, a CAT score of 16 was the optimal cut-off point for 
an mMRC dyspnea score of 2. On the other hand, a CAT 
score of 10 was the optimal cut-off point for a score of 1 
on the mMRC dyspnea scale. Our results are consistent 
with those obtained in other studies where both assessment 
methods have been compared, also concluding that the 
currently established cut-off points are not similar.7,24–26 
Thus, we propose that in future updates of the GOLD 
strategy, a readjustment should be made and new cut-off 
points planned to separate highly symptomatic patients 
from those who are mildly symptomatic.
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